Should Biotech Investors Fear Dilution?
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
Saturday, July 21, 2018
Should Biotech Investors Fear Dilution?
Should Biotech Investors Fear Dilution?
Biotechs are infamous for tapping the public markets for capital on a regular basis. Here is a look at how this standard practice can both damage and create value for shareholders.
Related Posts:
Oil prices rise amid Gulf of Mexico storm, Middle East tensions- Asian shares ease as Trump rekindles Sino-U.S. trade tensions
- Air China to buy 20 A350-900 wide-body aircraft from Airbus
- Asian shares dart between gains and losses before key China data
- Oil near six-week highs amid Gulf of Mexico storm, Middle East tensions
0 comments:
Post a Comment